A Study of LY3502970 in Participants With Impaired and Normal Liver Function

NCT05882032 · Completed

Last updated 2026-05-28

This study is testing how a drug called LY3502970 is processed in the body by people with normal liver function and those with liver problems.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 29 people

Who can join Ages 18–80 · all sexes Healthy volunteers accepted.

Timeline Started 2023-06 · est. completion 2024-11

Where 4 sites · United States

What this study is testing ClinicalTrials.gov NCT05882032 ↗

Description as written by the study sponsor.

The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.

Treatments tested

LY3502970 Drug

Administered orally.

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of LY3502970
Sponsor	Eli Lilly and Company
Conditions studied	Healthy, Hepatic Insufficiency
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05882032 ↗